← All trials
NCT07215923
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Oct 14, 2025
- Last posted
- Oct 15, 2025
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Antidote Therapeutics, IncLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- National Institutes of Health (NIH)Collaborator
- Antidote Therapeutics, IncOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.